Comparative assessment of three different second-line regimens in chemotherapy resistant / refractory small-cell lung cancer

Basit Öğe Kaydı
dc.authoridçakır, emre/0000-0003-0411-8818
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405;
dc.authorwosidçakır, emre/JVZ-2045-2024
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidDemirci, Ayşe/GWZ-5265-2022
dc.authorwosidBilir, Cemil/A-2491-2017
dc.contributor.authorHacibekiroglu, Ilhan
dc.contributor.authorOzkul, Ozlem
dc.contributor.authorCakir, Emre
dc.contributor.authorKostek, Osman
dc.contributor.authorKaratas, Fatih
dc.contributor.authorEsenkaya, Asim
dc.contributor.authorDemirci, Ayse
dc.date.accessioned2024-06-12T11:14:15Z
dc.date.available2024-06-12T11:14:15Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: Small cell lung cancer (SCLC) patients unresponsive or relapsing within 90 days following frontline chemotherapy have poor prognosis and they should be treated with different chemotherapy regimens other than those used in the first-line regimen. Currently there is no globally accepted standard chemotherapeutic regimen for the treatment of these patients. This retrospective study was designed to compare CAV (Cyclophosphamide, Doxorubicin, Vincristine), weekly topotecan and weekly irinotecan regimens and to evaluate the efficacy of the three regimens in patients with chemotherapy resistant/refractory (CRR) SCLC. Methods: A total of 67 CRR-SCLC patients, who were treated with CAV, weekly topotecan and weekly irinotecan were reviewed for weekly irinotecan (27 for 60 mg/m(2) intravenously on days 1, 8 and 15 of a 28-day cycle, 24 for CAV (Cyclophosphamide 750 mg/m(2) on day 1, Doxorubicin 50 mg/m(2) on day 1 and Vincristine 1.4 mg/m(2) on day 1 every 3 weeks), 16 for weekly topotecan (4 mg/m(2) intravenously on days 1, 8 and 15 of a 28-day cycle). Results: The median follow-up time was 12.45 months, there was no difference about disease control rates (DCR) between three chemotherapy regimens (DCR; 25.9% with irinotecan, 29.2% with CAV and 31.3% with topotecan, p=0.92). Objective response rates (ORR) for irinotecan, CAV and topotecan groups were 3,7%, 8,8%, and 0%, respectively (p=0.63). Median progression free survival (PFS) and overall survival (OS) were similar according to irinotecan, CAV, and topotecan (PFS: 1.93 months, 2.30 months and 3.45 months; OS: 2.89 months, 4.79 months and 5.81 months, respectively). The adverse events were generally mild and manageable for both hematological and nonhematological toxicities in all three arms. Conclusions: Weekly irinotecan, CAV and weekly topotecan are similarly effective and safe chemotherapy protocols for the treatment of CRR-SCLC patients.en_US
dc.identifier.endpage86en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue1en_US
dc.identifier.pmid33721436en_US
dc.identifier.startpage79en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23866
dc.identifier.volume26en_US
dc.identifier.wosWOS:000642341900011en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSmall Cell Lung Canceren_US
dc.subjectPlatinum Resistanceen_US
dc.subjectCAVen_US
dc.subjectIrinotecanen_US
dc.subjectTopotecanen_US
dc.titleComparative assessment of three different second-line regimens in chemotherapy resistant / refractory small-cell lung canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu